Zoetis Inc. (NYSE:ZTS) Shares Purchased by GeoWealth Management LLC

GeoWealth Management LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,838 shares of the company’s stock after buying an additional 402 shares during the quarter. GeoWealth Management LLC’s holdings in Zoetis were worth $951,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Norges Bank purchased a new stake in shares of Zoetis in the 4th quarter valued at $824,321,000. Wellington Management Group LLP lifted its holdings in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after buying an additional 3,059,255 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Zoetis in the 4th quarter valued at approximately $196,651,000. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after acquiring an additional 1,116,541 shares in the last quarter. Finally, Amundi raised its stake in shares of Zoetis by 46.2% in the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock valued at $453,355,000 after acquiring an additional 867,993 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $214.40.

Insiders Place Their Bets

In other news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by insiders.

Zoetis Price Performance

Shares of NYSE ZTS opened at $148.64 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market cap of $66.32 billion, a P/E ratio of 27.17, a P/E/G ratio of 2.78 and a beta of 0.92. The stock has a 50 day moving average of $160.04 and a two-hundred day moving average of $169.80. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. On average, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.35%. Zoetis’s dividend payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.